Sponsored Links
| Clavis Pharma's Elacytarabine Granted FDA Fast Track Designation In USA |
 |
 |
 |
| Medical News - Lymphoma and Leukemia | |||
|
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that its clinical development programme with elacytarabine for the treatment of patients with acute myeloid leukaemia (AML) has been granted Fast Track designation by the US Food & Drug Administration (FDA)... Read more: Lymphoma / Leukemia / Myeloma News From Medical News Today
|